{
    "paper_id": "e7e7d9137300fc4f6fd96d0208f4052dce65c2c2",
    "metadata": {
        "title": "9.1 Neutropenic Sepsis",
        "authors": [
            {
                "first": "H",
                "middle": [],
                "last": "Bertz",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "Systemic reaction to an infection during neutropenia (particularly after chemotherapy or radiotherapy).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "\u2022 Severe sepsis: temperature > 38.0\u00b0C or < 36\u00b0C, heart rate > 90/min, respiratory rate > 20/min or PaCO2 < 32 mmHg \u2022 Septic shock: hypotension with blood pressure (BP) < 90 mmHg (systolic) or BP decrease by 40 mmHg and signs of organ failure: lactate acidosis, oliguria, multiorgan failure (MOF)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Fever during neutropenia (FN; 7 Chap. 4.2) is a common side effect after myelosuppressive chemotherapy or radiotherapy; the incidence correlates directly with length and severity of the neutropenia. Up to 15% of patients with febrile neutropenia develop severe sepsis or septic shock.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Risk factors \u2192 neutropenia \u2192 febrile neutropenia \u2192 sepsis",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "\u2022 Low risk: granulocytes 0.5-1 \u00d7 109/l for 2-7 days \u2192 in case of sepsis, mortality 14% \u2022 High risk: granulocytes < 0.1 \u00d7 109/l for > 7-10 days \u2192 in case of sepsis, mortality 47%",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Both proinflammatory (TNF\u03b1, IL-6, IL-8) and antiinflammatory (IL-1 RA, IL-10) cytokines play an important role.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "\u2022 Fever, general symptoms, weakness, reduced performance \u2022 Local signs of inflammation: catheter infection, skin infections, mucositis, gingivitis, acral focal infections, abscesses \u2022 Sinusitis, signs of pulmonary infection \u2022 Gastrointestinal symptoms, pain, diarrhea \u2022 Meningitis, headache, amentia \u2022 Sepsis: decrease in blood pressure, tachycardia, hypothermia",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "\u2022 Medical history (fever, diarrhea, dysuria, etc.) \u2022 Physical examination: intravenous access sites, catheter ports, skin, oral mucous membranes, perianal region, pulmonary auscultation and percussion, abdominal pressure pain, pain on tapping / pressure pain of the paranasal air sinuses, lymphadenopathy, monitoring of blood pressure and pulse, meningism",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "\u2022 Routine laboratory tests, parameters of inflammation, plasmic coagulation, antithrombin III (ATIII), plasminogen activator inhibitor (PAI 1), liver and renal function tests",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "\u2022 Peripheral blood cultures and cultures from intravenous access and catheters (7 Chap. 10.8).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Aerobic and anaerobic blood culture, isolator tube bottle. Where applicable, remove catheter, microbiological analysis of the catheter tip. \u2022 Urine culture, sputum culture, swabs from suspicious lesions, lumbar / pleural / ascites puncture and culture \u2022 With pulmonary infiltrates: bronchoalveolar lavage (BAL) \u2022 With diarrhea: stool culture, detection of enterotoxins from Clostridium difficile, Gruber-Widal",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "\u2022 Chest x-ray, possibly x-ray of paranasal air sinuses \u2022 Abdominal ultrasound if indicated \u2022 High-resolution CT scan if indicated",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Imaging"
        },
        {
            "text": "With fever during neutropenia, rapid initiation of treatment is essential: 1. Microbiological analysis 2. Immediate initiation of empirical antibiotic treatment: broad-spectrum antibiotic with effectiveness against pseudomonas spp., where applicable in combination with an aminoglycoside and a glycopeptide (particularly in case of catheter sepsis). Rapid escalation with antimycotics has proven benefit (amphotericin B, lipid formulation amphotericin B, azoles, echinocandins) (7 Chap. 4 .2) 3. Optimization of tissue oxygenation. Administration of oxygen via nasal tube or mask, 2 l/min up to 12 l/min. Where applicable, respiration support (non-invasive: CPAP; invasive: intubation) 4. Volume substitution; where applicable, administration of catecholamines 5. Initiate intensive medical care at an early stage",
            "cite_spans": [
                {
                    "start": 478,
                    "end": 488,
                    "text": "(7 Chap. 4",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Emergency Treatment"
        },
        {
            "text": "\u2022 Further diagnosis (imaging, ultrasound, bronchoalveolar lavage (BAL), abscess aspiration / biopsy, etc.) \u2022 In case of impaired renal function, initiate dialysis \u2022 If persistence of neutropenia is expected, administer G-CSF to support bone marrow reconstitution. (7 Chap. 4.3) . Activated protein C demonstrated a positive effect on the overall survival of septic patients, but with marked side effects. Consider granulocyte transfusion (7 Chap. 5.4) .",
            "cite_spans": [
                {
                    "start": 264,
                    "end": 277,
                    "text": "(7 Chap. 4.3)",
                    "ref_id": null
                },
                {
                    "start": 438,
                    "end": 451,
                    "text": "(7 Chap. 5.4)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Further Measures"
        },
        {
            "text": "\u2022 Basic hospital hygiene; conduct of invasive procedures under aseptic conditions \u2022 Patient hygiene, especially skin care, dental care, mucositis prophylaxis; avoid foods with high germ counts \u2022 If neutropenia persists for more than 7 days: regular monitoring, even if apyrexial \u2192 blood cultures, fecal cultures, throat swabs, sputum. Consequent treatment of fever in neutropenia (7 Chap. 4 .2) \u2022 Administration of hematopoietic growth factors (G-CSF) according to current guidelines (ASCO / ESMO guideline; (7 Chap. 4.3) Aapro MS, Cameron DA, Pettengell R et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. ",
            "cite_spans": [
                {
                    "start": 380,
                    "end": 390,
                    "text": "(7 Chap. 4",
                    "ref_id": null
                },
                {
                    "start": 508,
                    "end": 521,
                    "text": "(7 Chap. 4.3)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Further Measures"
        },
        {
            "text": "Occurrence with various solid tumors and hematological neoplasia \u2192 most common: lung cancer, breast cancer, prostate cancer, melanoma, lymphoma, multiple myeloma.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Etiology"
        },
        {
            "text": "Usually extracordal compression of spinal cord or cauda equina: \u2022 Tumor invasion from the vertebral body into the epidural space \u2192 spinal cord compression (common with lung cancer, breast cancer) \u2022 Tumor invasion through the intervertebral foramina \u2192 spinal cord compression or nerve root compression (lymphoma) \u2022 Direct metastasis into the spinal canal (rare) \u2022 Tumor-induced vascular damage \u2192 malperfusion, spinal cord damage due to infarction \u2022 Paraneoplastic syndromes (7 Chap. 8.13) Location of spinal cord compression: \u2022 Cervical: 10% \u2022 Thoracic: 70% \u2022 Lumbosacral: 20% \u2022 Multifocal: 25%",
            "cite_spans": [
                {
                    "start": 473,
                    "end": 487,
                    "text": "(7 Chap. 8.13)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Mechanisms of Tumor-Induced Spinal Cord Damage"
        },
        {
            "text": "Often protracted process over a longer period of time, however, neurological deficits may develop within a few hours (especially with rapidly proliferating neoplasia such as lung cancer, renal cell carcinoma, melanoma, or lymphoma). \u2022 Most common symptom: pain (> 90% of patients) as \"back ache, \" \"lumbar syndrome, \" etc. \u2022 Radicular deficits: dermatoma-specific sensory and motor deficits; band-like pain; in some cases unilateral \u2022 Segmental myelopathy: motor deficits / paresis, segmental sensory deficits \u2022 Generalized myelopathy: bilateral motor disorders / pareses, sensory deficits; compression around cauda equina: \"saddle anesthesia, \" bladder / colon paralysis, anal sphincter tone \u2193, tendon reflexes \u2191, positive Babinski's sign Severe hemodynamically significant pericardial effusion caused by tumor invasion of the pericardium or myocardium. Medical emergency.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Mechanisms of Tumor-Induced Spinal Cord Damage"
        },
        {
            "text": "Invasion of pericardium or myocardium in up to 15% of patients with solid tumors.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Medical History, Physical Examination"
        },
        {
            "text": "Direct invasion or lymphatic / hematogenous metastasis to the pericardium or myocardium in patients with solid tumors and hematological neoplasia.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Medical History, Physical Examination"
        },
        {
            "text": "Metastasis to the pericardium / myocardium \u2192 Pericardial effusion, arrhythmia \u2192 Cardiac tamponade (critical effusion volume in cases of rapid onset: 300-400 ml) \u2192 Diastolic dysfunction ( ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cardiac Tamponade"
        },
        {
            "text": "Physical examination: rise in jugular venous pressure (increased on inspiration = Kussmaul's sign), pulsus paradoxus (end-inspiratory decrease in blood pressure by > 10 mmHg), muffled heart sounds, pulmonary rales, hepatosplenomegaly, ascites, edema",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Medical History, Physical Examination"
        },
        {
            "text": "\u2022 Chest x-ray: enlarged heart silhouette \u2022 ECG changes are usually unspecific, sometimes electrical alternans and/or precordial low voltage; with concurrent pericarditis: sinus tachycardia, raised ST, changes in T-wave \u2022 Echocardiography (most important diagnostic tool) \u2022 In selected cases: right heart catheterization, angiocardiography ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Imaging"
        },
        {
            "text": "\u2022 Osteoclast activation and proliferation \u2192 increased bone destruction, calcium release \u2022 Inhibition of osteoblast activity \u2192 reduced bone regeneration \u2022 Glomerular filtration rate \u2193 , tubular calcium reabsorption \u2191 The majority of patients with moderate hypercalcemia are asymptomatic. Symptoms of advanced hypercalcemia (> 2.7 mmol/l) or hypercalcemic crisis (> 3.5 mmol/l): ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Consequences"
        },
        {
            "text": "Hyperuricemia:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5."
        },
        {
            "text": "\u2022 Rasburicase (recombinant urate oxidase) 0.2 mg/kg/day, for 5-7 days. ATTEN-TION: for measurement of uric acid during treatment with rasburicase use cooled serum; otherwise inaccurate (low) readings.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5."
        },
        {
            "text": "Renal dysfunction / acute oliguria:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "6."
        },
        {
            "text": "\u2022 Dopamine 100-200 mg/24 h (infusion pump); benefit not fully established.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "6."
        },
        {
            "text": "\u2022 Dialysis (after exclusion of urinary tract obstruction)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "6."
        },
        {
            "text": "Close monitoring: ECG, central venous pressure (CVP, target: > 5), routine laboratory tests (urea + electrolytes, serum creatinine, bilirubin, uric acid)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Further Measures"
        },
        {
            "text": "\u2022 Identification of high-risk patients (acute leukemias, Burkitt's lymphoma, high-grade non-Hodgkin's lymphomas, high tumor burden) \u2022 Sufficient rehydration (target: > 2.5 l urine daily) while monitoring CVP \u2022 Alkalization (target: urinary pH > 7) with NaHCO3 p.o. or citrate p.o., intravenous bicarbonate (if required) \u2022 Xanthine oxidase inhibitors (allopurinol 300 mg/day) \u2192 if not tolerated: benzbromarone (uricosuric agent) ATTENTION: allopurinol inhibits the metabolization of 6-mercaptopurine, azathioprine, theophylline, and phenprocoumon \u2192 if given with allopurinol, the dose of 6-mercaptopurine must be lowered to 25%. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Most important: detection of risk factors and appropriate prophylaxis prior to initiation of treatment in high-risk patients:"
        },
        {
            "text": "Acute or subacute hemorrhagic inflammation of the mucous membrane of the urinary bladder, usually treatment-induced (cyclophosphamide, ifosfamide, radiotherapy)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hemorrhagic Cystitis"
        },
        {
            "text": "Hematuria, pollakiuria, pain",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hemorrhagic Cystitis"
        },
        {
            "text": "Bladder irrigation; often spontaneous cessation. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Mild Hemorrhage"
        },
        {
            "text": "Complications occurring after transfusion of cellular blood products (packed red cells and platelet concentrates), fresh frozen plasma (FFP), coagulation factors, immunoglobulins, or human albumin. Transfusion reactions are classified according to pathogenesis, type of blood product, time of occurrence, and clinical picture.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "H. Hen\u00df"
        },
        {
            "text": "Incidence: approximately 1-10% of all transfusions.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Acute Transfusion Reactions"
        },
        {
            "text": "\u2022 Most dangerous form of acute transfusion reactions, incidence 1:6,000 to 1:25,000 transfusions, 0.75 deaths per 100,000 transfusions \u2022 Major ABO incompatibility \u2192 severe acute intravascular hemolysis with complement activation and cytokine release \u2022 In rare cases, irregular preformed antierythrocytic allo-or autoantibodies in the recipient (Kell system, Kidd system, Duffy system, etc.)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Acute Hemolytic Transfusion Reaction (AHTR)"
        },
        {
            "text": "\u2022 Most common transfusion reaction, 5% of all transfusions \u2022 Post-transfusion temperature increase by \u2265 1\u00b0C with no signs of hemolysis or other transfusion-induced reactions \u2022 Pathogenesis: antibodies against platelets or leukocytes, active mediator release from viable leukocytes contained in the blood product (e.g., cytokines), bacterial contamination (very rare)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Febrile Non-hemolytic Transfusion Reaction (FNHTR)"
        },
        {
            "text": "\u2022 Local or generalized allergic reaction to plasma proteins \u2022 In case of local urticarial reaction: transfusion may be continued after antihistamine treatment (all other cases of transfusion reactions: stop the transfusion, return blood product to blood bank, see below)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Urticarial Reaction"
        },
        {
            "text": "\u2022 Patients with congenital IgA deficiency (incidence 1:700) and presence of IgA antibodies. In the majority of cases, pathogenesis not clear.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Anaphylactic Reaction to Plasma-containing Products (Platelet Concentrates, FFP)"
        },
        {
            "text": "\u2022 Granulocyte-or monocyte-specific antibodies (HLA class I or II) in the donor plasma react with leukocyte antigens in the recipient (in rare cases, reverse antibody constellation) \u2192 agglutination and activation of granulocytes and monocytes, especially in the lungs \u2022 Rare and potentially fulminant ARDS-like reaction occurring 1-6 h after transfusion; lethal in approximately 15%",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Transfusion-related Acute Lung Injury (TRALI)"
        },
        {
            "text": "\u2022 Citrate intoxication ( . Transfusion Reactions",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Non-immunological Side Effects (esp. with Massive Transfusions)"
        },
        {
            "text": "Extravasation / paravascular administration of cytostatic drugs.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "H. Bertz"
        },
        {
            "text": "Extravasation in 0.1-0.5% of all cases of intravenous administration of cytostatic drugs. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "H. Bertz"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Cytomegalovirus (CMV)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Leukocyte-depleted cellular blood products are equally low risk as anti-CMV-negative blood products (according to guidelines). However, high-risk patients (e.g., anti-CMV-negative recipient of allogenic stem cell transplant, intrauterine transfusion) should strictly receive anti-CMV-negative blood products \u2022 CMV reactivation / CMV coinfection in anti-CMV-positive immunosuppressed recipients by administration of blood products is unlikely",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "PV-B19): transfusions from PV-B19-IgG-positive donors recommended in patients needing regular transfusions \u2022 HTLV I/II: risk identification and sequential testing of donors for HTLV I/II is recommended \u2022 EBV (Epstein-Barr virus",
            "authors": [],
            "year": null,
            "venue": "Other Transfusion Relevant Viruses \u2022 Parvovirus B19",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "hepatitis G virus): relevance in relation to transfusions as yet uncertain \u2022 TTV (transfusion-transmitted virus): isolated in 1998, significance as yet uncertain Other Transfusion Relevant Infectious Agents \u2022 Bacteria: bacterial contamination is rare with sterile preparation and use of single-use materials",
            "authors": [
                {
                    "first": "\u2022",
                    "middle": [],
                    "last": "Hgv",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "\u2022 Parasitic diseases: malaria, babesiosis, Chagas' disease etc; preventable by temporary abstinence from blood donation after travel to affected regions",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "CJD) / new variant CJD (vCJD): so far, no scientific data on transmission through blood products, however this possibility can not be definitively excluded. Individuals potentially at risk of CJD infection due to their medical history (e.g., treatment with human growth hormone derived from pituitary glands of corpses",
            "authors": [
                {
                    "first": "\u2022 Creutzfeldt-Jakob",
                    "middle": [],
                    "last": "Disease",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Pathophysiology of hemolytic transfusion reactions",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "D"
                    ],
                    "last": "Davenport",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Semin Hematol",
            "volume": "42",
            "issn": "",
            "pages": "165--174",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "New technology for transfusion safety",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "H"
                    ],
                    "last": "Dzik",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Br J Haematol",
            "volume": "136",
            "issn": "",
            "pages": "181--90",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Risks of transfusion-transmitted infections",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "J"
                    ],
                    "last": "Pomper",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "L"
                    ],
                    "last": "Snyder",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Curr Opin Hematol",
            "volume": "10",
            "issn": "",
            "pages": "412--420",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Transfusion Reactions",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Popovsky",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Transfusion-associated graft-versus-host disease",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Schroeder",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Br J Haematol",
            "volume": "117",
            "issn": "",
            "pages": "257--87",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Transfusion-related acute lung injury",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "C"
                    ],
                    "last": "Sillmann",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "R"
                    ],
                    "last": "Ambrusi",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "K"
                    ],
                    "last": "Boshkov",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Puget Sound Blood Ctr",
            "volume": "105",
            "issn": "",
            "pages": "2266--73",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Hematological and Oncological Emergencies Emergency Treatment Check pulse, local symptoms, and vital signs every 30 min Immediate therapy-even if no symptoms 1. Basic measures: \u2022 Stop infusion immediately",
            "authors": [],
            "year": null,
            "venue": "Pg: Pg: Ref: Ref: Web: Web: Part",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "\u2022 Place 5-ml syringe on i.v. access and extract extravasated fluid if possible",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Substance-specific measures: \u2022 Anthracyclines (doxorubicin, daunorubicin, epirubicin, idarubicin), anthracenediones (mitoxantrone), platinum compounds (cisplatin, carboplatin), and mitomycin C: DMS0 99% every 3-4 h for at least 3 days (up to 14 days) \u2192 apply with swab to the entire extravasation area and leave to dry. \u2022 Anthracyclines: dexrazoxane hydrochloride 1000 mg/m2/d i.v. 24 h and 48 h after extravasation",
            "authors": [],
            "year": null,
            "venue": "\u2022 In case of blistering or extensive extravasation: transcutaneous aspiration",
            "volume": "2",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Exception: etoposide, teniposide, vinblastine, vincristine, and vindesine: mild dry warmth (use blanket to keep extravasation site warm)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Surgical measures: \u2022 Progressive necrosis / ulceration: surgical debridement / removal of necrotic tissue / plastic surgery (flap)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Documentation: \u2022 All cases of extravasation as well as management and treatment must be accurately documented. may even cause additional toxicity: \u2022 Local application of corticosteroids, topical or subcutaneously (highly controversial",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "\u2022 Local infiltration of hyaluronidase \u2022 Local infiltration of NaHCO3 8.4%, sodium thiosulfate, or heparin (particularly with vinca alkaloids) cytostatic drugs: \u2022 For peripheral line: only use veins on the dorsum of the forearm, ensure good flow \u2022 Only use intravenous catheters \u2022 In patients with history of mastectomy, use contralateral arm for infusion (due to impaired lymph drainage and venous congestion after axillary dissection",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Px: \u2022 Ensure correct position of the intravenous line (erythema, swelling, induration, local pain); if in doubt: resite the i.v. line \u2022 Reliable fixation of the extremity, leave access visible \u2022 If placement of intravenous line was unsuccessful at first attempt, avoid puncturing the same vein distal to the original access point \u2022 Cytostatic drugs should only be added to a freely running infusion (NaCl 0.9% or glucose 5%); of cytostatic drugs of severe local toxicity via peripheral line",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "F/U: F/U: Px",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Extravasation and tissue necrosis due to central line infusions",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "G"
                    ],
                    "last": "Davies",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "C"
                    ],
                    "last": "Russell",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "P"
                    ],
                    "last": "Thompson",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Anaesthesia",
            "volume": "58",
            "issn": "",
            "pages": "820--821",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Extravasation of systemic hemato-oncological therapies",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "A"
                    ],
                    "last": "Ener",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "B"
                    ],
                    "last": "Meglathery",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Styler",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Ann Oncol",
            "volume": "15",
            "issn": "",
            "pages": "858--62",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Extravasation of chemotherapeutic agents: prevention and treatment",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "V"
                    ],
                    "last": "Goolsby",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "A"
                    ],
                    "last": "Lombardo",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Semin Oncol",
            "volume": "33",
            "issn": "",
            "pages": "139--181",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Totally implantable venous-access ports: local problems and extravasation injury",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "P"
                    ],
                    "last": "Kurul",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Saip",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Aydin",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Lancet Oncol",
            "volume": "3",
            "issn": "",
            "pages": "684--92",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Surgical treatment of extravasation injuries",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Napoli",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Corradino",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Badalamenti",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "J Surg Oncol",
            "volume": "91",
            "issn": "",
            "pages": "264--272",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Extravasation: a dreaded complication of chemotherapy",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "L"
                    ],
                    "last": "Schrijvers",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Ann Oncol",
            "volume": "14",
            "issn": "3",
            "pages": "26--30",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Managing vesicant extravasations",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Schulmeister",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Oncologist",
            "volume": "13",
            "issn": "",
            "pages": "284--292",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Ref: Web: Web: . Extravasation of Cytostatic Drugs",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "TABREF0": {
            "text": "Obstruction of the superior vena cava due to tumor compression, tumor-induced thrombosis, or other causes. Characteristic clinical picture of congestion of the superior vena cava. Underlying malignancy in 75-80% of cases. Headache, central nervous symptoms: 60% \u2022 Dyspnea, tachypnea, cyanosis, cough (occasionally): 60% \u2022 Dysphagia: 5% \u2022 Horner's syndrome (miosis, ptosis, enophthalmus): 3% Medical History, Physical Examination \u2022 Medical history (tumors, other risk factors) \u2022 Physical examination including venous congestion, neurological signs, lymphadenopathy, spleen",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Prognostic Factors\u2022 Time between diagnosis and initiation of therapy \u2022 Extent of neurological deficits before start of treatment \u2022 Nature of the primary tumorBagley CA, Gokaslan ZL. Cauda equina syndrome caused by primary and metastatic neoplasms. Neurosurg Focus 2004;16:e3 Byrne T. Spinal cord compression from epidural metastases. N Engl J Med 1992;327:614-7 Loblaw DA, Laperriere NJ. Emergency treatment of malignant extradural spinal cord compression: an evidence based guideline. J Clin Oncol 1998;16:1613-24 Maranzano E, Bellavita R, Rossi R et al. Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial. J Clin Oncol 2005;23:3358-65 Quinn JA, DeAngelis LM. Neurologic emergencies in the cancer patient. Semin Oncol 2000;27:311-21",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "ventricular load) \u2192 Cardiac insufficiency, cardiogenic shock Over 65% of pericardial and myocardial metastases are clinically asymptomatic. Symptoms develop with increasing severity and due to hemodynamic consequences of malignant pericardial effusion: \u2022 Dyspnea, cough, weakness, reduced performance \u2022 Retrosternal pain \u2022 Arrhythmia, tachycardia \u2022 Signs of cardiac insufficiency (jugular venous distension, hepatosplenomegaly, cyanosis) \u2022 Syncope",
            "latex": null,
            "type": "table"
        },
        "TABREF3": {
            "text": "CytologyDiagnostic pericardiocentesis with effusion analysis: \u2022 Total protein, LDH, glucose, triglycerides, cholesterol \u2022 Cell count, cytology, immunocytology \u2022 Microbiological diagnosis: cultures (including tuberculosis), Gram stain, Ziehl-Neelsen stain In cases of underlying malignancy: \u2022 Superior vena cava syndrome (SVCS, 7 Chap. 9.2) \u2022 Radiogenic pericarditis (as a result of radiotherapy) Treatment of cardiac tamponade / malignant pericardial effusion depends on symptoms, patient's performance status, and prognosis: \u2022 Asymptomatic effusion without hemodynamic significance: treatment not indicated \u2022 Terminal disease: individual assessment in each case Def: Def: Local treatment of confirmed malignant pericardial effusion: instillation of cytostatics (e.g., methotrexate 25 mg, cisplatin 20-200 mg, or bleomycin 30-60 mg). Pericardial fenestration, e.g., by inferior pericardiotomy. Radiotherapy: total dose of 25-35 Gy in 3-4 weeks, response rates of up to 60%. \u2022 Systemic treatment of the underlying disease: chemotherapy, particularly in previously untreated patients with chemosensitive malignancies (small cell lung cancer, lymphoma, leukemia). \u2022 Surgery: pleuropericardial fenestration; pericardiectomy only in selected cases (e.g., chronic radiogenic pericarditis)",
            "latex": null,
            "type": "table"
        },
        "TABREF4": {
            "text": "\u2022 Kidney: polyuria, polydipsia, dehydration \u2192 later anuria, acute renal damage, nephrocalcinosis, nephrolithiasis \u2022 Gastrointestinal tract: nausea, vomiting, weight loss, anorexia, gastroduodenal ulcers / pancreatitis (rare) \u2022 Muscle: muscle weakness, constipation, ileus \u2022 Cardiac: bradycardia, atrial and ventricular arrhythmias \u2022 CNS: fatigue, lethargy, impaired vision, psychosis, somnolence, coma \u2022 Routine laboratory tests including Ca 2+ , phosphate, K + , Na + , Cl \u2212 , urea and electrolytes, serum creatinine, bilirubin, alkaline phosphatase, albumin \u2022 Determination of serum PTH and, where applicable, PTH-RP \u2022 ECG: QT interval \u2193, PQ interval \u2193, T-wave (widened), bradycardia, arrhythmia \u2022 Imaging: exclusion of osteolysis (skull, vertebral column, pelvis, humerus, femur); with plas-Syndrome arising due to rapid destruction / decomposition of large amounts of tumor tissue with release of intracellular components, including K + , phosphate, and uric acid.",
            "latex": null,
            "type": "table"
        },
        "TABREF5": {
            "text": "Treatment is determined by the severity of the hemorrhage. Specification of the hemorrhage: local / punctate / diffuse / generalized \u2022 Specific hemostatic measures: endoscopic obliteration; where applicable: surgical intervention (vascular ligation, tumor extirpation), transarterial embolization (angiography and subsequent embolization)",
            "latex": null,
            "type": "table"
        },
        "TABREF6": {
            "text": "Bleeding\u2022 Irrigation with large urinary catheter \u2022 Removal of blood clots (if required, cystoscopically) \u2022 Intravesicular treatment, e.g., 1% alum or prostaglandin E2 and F2 \u2022 With circumscribed hemorrhage: possibly cystoscopic obliteration of the source of bleeding",
            "latex": null,
            "type": "table"
        },
        "TABREF7": {
            "text": "platelet concentrates, FFP) and alkalosis \u2022 Hypothermia, hypovolemia \u2022 Hyperkalemia (neonates, anuric patients), hypocalcemia \u2022 Embolism (rare), bacterial contamination (rare)Rapid onset after start of transfusion:\u2022 Shivers, fever, sweating, nausea, vomiting \u2022 Skin reactions, urticaria, flush, pruritus (particularly with allergic transfusion reactions)",
            "latex": null,
            "type": "table"
        },
        "TABREF8": {
            "text": "Acute Reaction\u2022 Edema, erythema, pain, hyperthermia \u2022 Potential systemic reactions: vasovagal reaction, nausea, vomitingDelayed Symptoms\u2022 Compounds of severe local toxicity: tissue necrosis / ulceration from day 7 \u2022 Superinfection of skin lesions Local allergic reactions (\u2192 topical corticoid treatment is advisable)B. Lubrich, H. Hen\u00df",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "Prophylactic treatment with mesna after cyclophosphamide / ifosfamide therapy. Severe hemorrhage may require surgery.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "annex"
        },
        {
            "text": "Coughing up of large quantities of blood (bright red and foamy = arterial, dark = venous), usually vascular erosion by malignant tumor.Emergency bronchoscopy, if possible: local coagulation, blockade / tamponade with balloontipped catheter",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Severe Hemoptysis"
        },
        {
            "text": "Vomiting of large quantities of blood, due to a bleeding malignant tumor, hemorrhagic gastritis / mucositis, vascular erosion.Endoscopy, local coagulation, if necessary: emergency surgery",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Severe Hematemesis"
        },
        {
            "text": "Hemorrhage in the upper gastrointestinal tract (melena) or lower gastrointestinal tract (bright red blood in stools). ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Melena (Tarry Stools) / Hematochezia (Perianal Hemorrhage)"
        },
        {
            "text": "\u2022 Retain blood bag (forensic reasons) \u2022 Return blood bag and a recent blood sample of the patient to the blood bank \u2192 Retesting of serological compatibility (before/after reaction), ABO compatibility between blood product and patient's blood, direct antiglobulin test, screening for irregular antibodies, bacteriological examination of the blood product ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Notification of the Blood Bank (Side Effects of Medicinal Products)"
        },
        {
            "text": "Supportive treatment (depending on the severity / cause of the reaction): oxygen, blood pressure, stabilization, diuresis maintenance with fluids and/or osmodiuretics (mannitol); TRALI: early ventilation support may be required",
            "cite_spans": [],
            "ref_spans": [],
            "section": "4."
        },
        {
            "text": "Prednisolone 100 mg i.v., alternatively: dexamethasone 8 mg i.v.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5."
        },
        {
            "text": "\u2022 Volume substitution, alkalinization, monitoring of urinary output to prevent acute renal failure; with impending acute renal failure: hemodialysis; ATTENTION: hyperkalemia due to potassium release from erythrocytes \u2022 Continued antiallergic treatment: steroids, antihistamines \u2022 Close monitoring of coagulation parameters, exclusion of DIC (7 Chap. 6.5.5) ATTENTION: do not underestimate the dynamics of acute transfusion reactions. Patients may require intensive care from an early stage.",
            "cite_spans": [
                {
                    "start": 341,
                    "end": 356,
                    "text": "(7 Chap. 6.5.5)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Further Measures"
        },
        {
            "text": "\u2022 Development of platelet-specific alloantibodies \u2192 severe thrombocytopenia approximately 5-9 days after transfusion involving the patient's own platelets (\"innocent bystander\"), usually occurring in women between 50 and 70 years of age \u2022 Treatment: intravenous IgG (avoid platelet transfusion)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Post-transfusion Purpura (Packed Red Cells or Platelet Concentrates)"
        },
        {
            "text": "\u2022 Primary immunization or boosting of alloantibodies \u2192 delayed hemolysis, usually few clinical symptoms \u2022 Diagnosis: immunohematological re-examination, hemolytic parameters",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Delayed Hemolytic Transfusion Reaction (DHTR)"
        },
        {
            "text": "Reaction of proliferating donor T-lymphocytes to the recipient; occurring with transfusion of immunosuppressed patients and transfusion of blood relatives (\"one-way HLA match\") \u2022 Engraftment of transfused cells \u2022 Later: transfusion-associated graft-versus-host disease (tGvHD) \u2022 After latent period of 20-60 days, skin manifestations (dermatitis), intestinal symptoms (gastroenteritis), hepatitis; often not associated with transfusion due to latency period, mortality rate of up to 90% \u2022 Diagnosis: detection of donor lymphocytes, DNA fingerprinting, skin biopsies \u2022 Prophylaxis: irradiation of blood products (indications: 7 Chap. 4.9.1)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Transfusion-associated Graft-versus-Host Reaction (tGvHR)"
        },
        {
            "text": "Iron deposition in the tissue due to iron overload by a factor of \u2265 5 (normal iron level: men 3.5 g, women 2.2 g). Rule of thumb: in chronically transfused patients risk of hemosiderosis after \u2265 100 packed red cell transfusions (approximately 250 mg iron per transfusion).Symptoms depending on the affected organs: \u2022 Hepatic dysfunction, diabetes mellitus, endocrine disturbances \u2022 Dark pigmentation of the skin (\"bronze diabetes\") \u2022 Cardiomyopathy, arrhythmia ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hemosiderosis"
        },
        {
            "text": "Risk with cellular products: < 1: 1,000,000 \u2192 further minimized due to introduction of HIV genome testing of donors by nucleic acid amplification; significantly lower risk with cell-free products (FFP, immunoglobulins, and coagulation factor products) due to quarantine or virus inactivation.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Human Immunodeficiency Virus (HIV)"
        },
        {
            "text": "Risk with cellular products: 1:50,000 to 1:200,000; significantly lower risk with cell-free products (due to quarantine or virus inactivation).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hepatitis B Virus (HBV)"
        },
        {
            "text": "Risk with cellular products: < 1:500,000; risk minimization possible by statutory nucleic acid amplification testing (HCV-NAT) of cellular blood products; significantly lower risk with cell-free products (due to quarantine or virus inactivation).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hepatitis C Virus (HCV)"
        }
    ]
}